VERU) shares, following the announcement of encouraging trial results. With the stock currently trading at $0.62, this represents a significant upside potential. According to InvestingPro data ...

William Wood’s rating is based on Veru Inc.’s promising results from ... Oppenheimer also reiterated a Buy rating on the stock with a $5.00 price target. TipRanks tracks over 100,000 company ...

$VERU insiders have traded $VERU stock on the open market 2 times in the past 6 months. Of those trades, 2 have been purchases and 0 have been sales. Here’s a ...

Gladstone Institutional Advisory LLC increased its stake in Veru by 34.2% during the 3rd quarter. Gladstone Institutional Advisory LLC now owns 56,876 shares of the company’s stock valued at $ ...

Elevate your confidence by analyzing investor sentiment and stock portfolio shifts, then make your own decisions.

Shares of VERU stock opened at $0.56 on Wednesday. The company has a market capitalization of $81.97 million, a price-to-earnings ratio of -2.00 and a beta of -0.54. Veru has a 1-year low of $0.36 ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Veru has transitioned into a late clinical-stage biopharmaceutical company, concentrating on cardiometabolic and inflammatory diseases. CEO Mitchell Steiner highlighted enobosarm and sabizabulin ...

This feature is currently unavailable; we are sorry for the inconvenience to you. Nasdaq Analyst Research provides analyst research for ratings consensus and a summary of stock price targets.